Summit Therapeutics Highlights Ivonescimab Poster at WCLC 2025
Summit Therapeutics shared a post on LinkedIn:
“Are you attending WCLC 2025? Then please MARK YOUR CALENDARS to view –ivonescimab Akeso poster: P1.11.83. Ivonescimab vs. Pembrolizumab for PD-L1-Positive NSCLC: A Subgroup Analysis of HARMONi-2 by Tumor Histology Presenter: Dr Anwen Xiong, Date/Time: Sunday, September 7, 2025, 10:30 – 12:00pm CEST, Location – Exhibit Hall
Important Summit WCLC 2025 Quick Facts – This link has what you need to know.
We look forward to seeing you in Barcelona Spain at Summit’s Medical Affairs Booth 204!
*Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA).”
More posts featuring Summit Therapeutics on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023